South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Indian Stock Market Drops as Iran Conflict Fuels Oil Price and Inflation Fears 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Kuaishou Stock Jumps on Kling AI IPO Plans and $20 Billion Valuation 
Moderna has filed a lawsuit against Pfizer and BionNTech over its mRNA technology that was used to produce COVID-19 vaccines. The American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, is suing for patent infringement, and this was filed last week.
Moderna also publicly announced its move to go after Pfizer and BioNTech as it believes that the latter copied its technology to make the COVID-19 vaccine Comirnaty. The company said it had filed patents for this between 2010 and 2016.
The patents were said to cover the company’s mRNA technology which is groundbreaking science that was important to the development of Moderna's mRNA COVID-19 vaccine called the Spikevax.
"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," Stephane Bancel, Moderna’s chief executive officer, said in a press release. "This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck.”
In response, Pfizer said that the lawsuit against them was unexpected and denied it had infringed any of Moderna’s patents. Pfizer and BionNTech said they have not yet fully reviewed the surprising complaint but vowed they would face the litigation to defend and quash all the allegations concerning patent infringement.
In a written statement that was sent to CNN, Pfizer further said that they are confident in their intellectual property as their own COVID-19 vaccine was based on BioNTech's proprietary mRNA technology. The vaccine was also co-developed by Pfizer and BioNTech.
BioNTech said in a statement that it is aware of the reports that it was sued and accused of copying some patents from Moderna. The company firmly stated that all of its work is original, so it will vigorously defend against these patent infringement allegations.
Meanwhile, Moderna said that while it has sued Pfizer and BioNTech, it is not aiming to pull out Pfizer's COVID-19 vaccine from the market. It is not planning to stop its future sales or seek damages for its sale, and what Moderna wants is simply a cut of its competitor's profits, as per Christopher Morten, who is an intellectual property law expert at Columbia University.
